Biogen Idec Inc. - TYSABRI US Reintroduction FDA Approval Call - Research and Markets offers a transcript of 'Biogen Idec Inc.' Conference Call.DUBLIN, Ireland -- The Biogen Idec Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BIIB BIIB Basic Imagery Interpretation Brief ) Corporate Conference Call took place on 6-Jun-06 8:30 a.m. ET. The Co. reported on 06/06/06 that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. has decided to allow TYSABRI back in the market and make it available to patients. BIIB believes that the reintroduction of TYSABRI offers new hope as an important therapeutic choice for patients living with a disabling and devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. disease. More information on this Conference Call can be obtained from Research and Markets at http://www.researchandmarkets.com/transcripts/90284 This document provides verbatim text of the conference call. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion